Illumina

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Illumina 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ILMN

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company was founded by David R. 

CEO
Jacob Thaysen
CEOJacob Thaysen
Employees
8,600
Employees8,600
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
8,600
Employees8,600

ILMN Key Statistics

Market cap
19.46B
Market cap19.46B
Price-Earnings ratio
23.38
Price-Earnings ratio23.38
Dividend yield
Dividend yield
Average volume
1.34M
Average volume1.34M
High today
$129.03
High today$129.03
Low today
$124.00
Low today$124.00
Open price
$124.47
Open price$124.47
Volume
952.50K
Volume952.50K
52 Week high
$155.53
52 Week high$155.53
52 Week low
$68.70
52 Week low$68.70

Stock Snapshot

The current Illumina(ILMN) stock price is $127.38, with a market capitalization of 19.46B. The stock trades at a price-to-earnings (P/E) ratio of 23.38.

During the trading session on 2026-04-03, Illumina(ILMN) shares reached a daily high of $129.03 and a low of $124.00. At a current price of $127.38, the stock is +2.7% higher than the low and still -1.3% under the high.

Trading activity shows a volume of 952.5K, compared to an average daily volume of 1.34M.

The stock's 52-week range extends from a low of $68.70 to a high of $155.53.

The stock's 52-week range extends from a low of $68.70 to a high of $155.53.

ILMN News

24/7 Wall St. 60m
The Personalized Biotech Flywheel Cathie Wood Built Is Still a Winning Bet Today

The Personalized Biotech Flywheel Cathie Wood Built Is Still a Winning Bet Today By Rich Duprey Published Apr 3, 8:52AM EDT Quick Read Illumina (ILMN) generat...

The Personalized Biotech Flywheel Cathie Wood Built Is Still a Winning Bet Today
Simply Wall St 3h
The Bull Case For Illumina Could Change Following A Board Refresh Centered On Regulatory Expertise

On April 2, 2026, Illumina announced that directors Frances Arnold, Robert S. Epstein, and Gary S. Guthart will retire from its board following the May 21, 2026...

The Bull Case For Illumina Could Change Following A Board Refresh Centered On Regulatory Expertise
TipRanks 1d
Illumina Announces Board Retirements and New Director Nominee

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Analyst ratings

48%

of 23 ratings
Buy
47.8%
Hold
39.1%
Sell
13%

More ILMN News

TipRanks 1d
Illumina announces board changes

Illumina (ILMN) announced changes to its Board of Directors. Frances Arnold, PhD, Robert Epstein, MD, and Gary Guthart, PhD, will retire from the Board in conne...

Simply Wall St 3d
Illumina Valuation Check As Labcorp Partnership Expands In Precision Oncology

Illumina (ILMN) just expanded its collaboration with Labcorp, centering investor attention on how next generation sequencing in precision oncology might influen...

Illumina Valuation Check As Labcorp Partnership Expands In Precision Oncology

People also own

Based on the portfolios of people who own ILMN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.